← All trials
NCT03895112
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2019
- Primary completion
- Mar 31, 2021
- Completion date
- Mar 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 24
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Icahn School of Medicine at Mount SinaiLead sponsor
- ForbiusCollaborator
- National Cancer Institute (NCI)Collaborator
- Icahn School of Medicine at Mount SinaiSponsor investigator
- Icahn School of Medicine at Mount SinaiStudy chair
- Icahn School of Medicine at Mount SinaiStudy director
- University of Texas, San AntonioStudy chair
- Myeloproliferative Neoplasm Research Consortium (MPN-RC)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.